Preparation, characterization and immunological evaluation: canine parvovirus synthetic peptide loaded PLGA nanoparticles

Abstract

BackgroundCanine parvovirus 2 (CPV-2) remains a significant worldwide canine pathogen and the most common cause of viral enteritis in dogs. The 1 L15 and 7 L15 peptides overlap each other with QPDGGQPAV residues (7-15 of VP2 capsid protein of CPV) is shown to produce high immune response. PLGA nanoparticles were demonstrated to have special properties such as; controlled antigen release, protection from degradation, elimination of booster-dose and enhancing the cellular uptake by antigen presenting cells. Nevertheless, there is no study available in literature, about developing vaccine based on PLGA nanoparticles with adjuvant properties against CPV.Thus, the aim of the present study was to synthesize and characterize high immunogenic W-1 L19 peptide (from the VP2 capsid protein of CPV) loaded PLGA nanoparticle and to evaluate their in vitro immunogenic activity.ResultsPLGA nanoparticles were produced with 5.26 ± 0.05 % loading capacity and high encapsulation efficiency with 81.2 ± 3.1 %. Additionally, it was evaluated that free NPs and W-1 L19 peptide encapsulated PLGA nanoparticles have Z-ave of 183.9 ± 12.1 nm, 221.7 ± 15.8 nm and polydispersity index of 0.107 ± 0.08, 0.135 ± 0.12 respectively. It was determined that peptide loaded PLGA nanoparticles were successfully phagocytized by macrophage cells and increased NO production at 2-folds (*P < 0.05) in contrast to free peptide, and 3-folds (*P < 0.01) in contrast to control.ConclusionIn conclusion, for the first time, W-1 L19 peptide loaded PLGA nanoparticles were successfully synthesized and immunogenic properties evaluated. Obtained results showed that PLGA nanoparticles enhanced the capacity of W-1 L19 peptide to induce nitric oxide production in vitro due to its adjuvant properties. Depend on the obtained results, these nanoparticles can be accepted as potential vaccine candidate against Canine Parvovirus. Studies targeting PLGA nanoparticles based delivery system must be maintained in near future in order to develop new and more effective nano-vaccine formulations.

Inhibition of melanoma metastasis by dual‐peptide PLGA NPS

“…[ ] Recently, many researchers have reported on the encapsulation of peptide into PLGA NPs to improve peptide‐based therapies. [ ] Ma et al developed a delivery system of PLGA NPs loaded with a tumor antigenic peptide vaccine and their results showed enhanced immune response in vivo . In the work of Amaral et al the encapsulation of an immunoprotective peptide in PLGA NPs increased therapeutic efficacy of a vaccine against paracoccidioidomycosis.…”

In vitro evaluations on canine monocyte-derived dendritic cells of a nanoparticles delivery system for vaccine antigen against Echinococcus granulosus

“…A number of studies have been carried out in vitro to characterize the interactions of different types of NPs with mouse or human dendritic cells [24,25]. In contrast, few studies have been performed on canine cells, and these studies are mainly based on macrophages [26,27]. To our knowledge, this work was the first to study canine dendritic cells and nanoparticle interactions.…”

Enhanced and Extended Anti-Hypertensive Effect of VP5 Nanoparticles

“…The supernatant after centrifuging the colloidal solution during the preparation of VP5-NPs was used to determine EE% and DL% of VP5-NPs as previously described [51] with minor modifications. Briefly, the amount of untrapped VP5 in supernatant was calculated by high performance liquid chromatography (HPLC, Waters Alliance 2695).…”